SCHEMBL5565433

SCHEMBL5565433

CONS(=O)(=O)c1ccc(C(C)=O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.56
CA9 Q16790 2/20 0.56
MEN1 O00255 5/20 0.55
KMT2A Q03164 5/20 0.55
MAPT P10636 2/20 0.54
HPGD P15428 2/20 0.54
FFAR4 Q5NUL3 1/20 0.53
CA1 P00915 2/20 0.51
CA2 P00918 2/20 0.51
ALDH1A1 P00352 4/20 0.50
CYP19A1 P11511 1/20 0.50
TP53 P04637 1/20 0.50
SLC1A3 P43003 1/20 0.49
SLC1A2 P43004 1/20 0.49
SLC1A1 P43005 1/20 0.49
GAA P10253 2/20 0.48
LMNA P02545 3/20 0.48
ALOX12 P18054 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5565789 0.79 CA12 (0.61) CA12CA9MEN1KMT2AMAPT
SCHEMBL419933 0.77 CA12 (0.59) CA12CA9MEN1KMT2AMAPT
SCHEMBL2039560 0.77 TSHR (0.67) CA12CA9MEN1KMT2AMAPT
SCHEMBL6554634 0.76 GAA (0.59) CA12CA9MEN1KMT2AMAPT
SCHEMBL5565548 0.76 MEN1 (0.49) CA12CA9MEN1KMT2AMAPT
SCHEMBL28162569 0.76 MEN1 (0.57) CA12CA9MEN1KMT2AMAPT
SCHEMBL14676354 0.75 MEN1 (0.51) CA12CA9MEN1KMT2AMAPT
SCHEMBL6228003 0.75 CA1 (0.55) CA12CA9MEN1KMT2ACA1
SCHEMBL3062734 0.75 ALDH1A1 (0.43) CA12CA9MEN1KMT2AMAPT
SCHEMBL29288589 0.75 CA1 (0.55) MEN1KMT2AMAPTFFAR4CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 US disclosed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 US disclosed
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases CRABTREE ACQUISITION CO, LLC 2005-03-03 US disclosed
WO-2004108094-A2 SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES ATHEROGENICS, INC. (US) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 CA12 1535/4885CA9 1619/4885MEN1 2929/4885
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 CA12 1535/4885CA9 1619/4885MEN1 2929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.